A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine
Phase of Trial: Phase II/III
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
- 01 Nov 2019 According to a Biohaven Pharmaceutical media release, United States Food and Drug Administration (FDA) has accepted the the new drug applications (NDAs) for rimegepant and expected Prescription Drug User Fee Act (PDUFA) date of the first quarter of 2020 for the Zydis orally dissolving tablet (ODT) formulation.
- 09 Sep 2019 Results presented in the Biohaven Pharmaceutical media release.
- 09 Sep 2019 According to a Biohaven Pharmaceutical media release, expanded data and post-hoc analyses from this trial were presented in the late breaking oral and poster sessions at the International Headache Conference in Dublin, Ireland.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History